Apogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) insider Carl Dambkowski sold 2,725 shares of the stock in a transaction dated Wednesday, June 4th. The shares were sold at an average price of $36.96, for a total transaction of $100,716.00. Following the completion of the transaction, the insider now owns 241,723 shares of the company's stock, valued at $8,934,082.08. This represents a 1.11% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Carl Dambkowski also recently made the following trade(s):
- On Wednesday, May 7th, Carl Dambkowski sold 2,725 shares of Apogee Therapeutics stock. The stock was sold at an average price of $35.75, for a total transaction of $97,418.75.
- On Wednesday, April 2nd, Carl Dambkowski sold 3,860 shares of Apogee Therapeutics stock. The shares were sold at an average price of $36.22, for a total transaction of $139,809.20.
Apogee Therapeutics Stock Performance
Shares of APGE stock traded up $3.33 during mid-day trading on Friday, hitting $40.98. The company's stock had a trading volume of 1,112,592 shares, compared to its average volume of 539,830. The stock has a market cap of $1.89 billion, a price-to-earnings ratio of -16.93 and a beta of 1.70. Apogee Therapeutics, Inc. has a 52-week low of $26.20 and a 52-week high of $63.50. The business has a 50-day moving average price of $36.28 and a 200 day moving average price of $39.58.
Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($0.95) earnings per share for the quarter, topping the consensus estimate of ($1.19) by $0.24. Equities research analysts predict that Apogee Therapeutics, Inc. will post -3.09 EPS for the current fiscal year.
Institutional Trading of Apogee Therapeutics
Several large investors have recently added to or reduced their stakes in APGE. Brooklyn Investment Group acquired a new stake in Apogee Therapeutics in the 1st quarter valued at about $42,000. GF Fund Management CO. LTD. purchased a new position in shares of Apogee Therapeutics during the 4th quarter worth approximately $43,000. AlphaQuest LLC acquired a new stake in shares of Apogee Therapeutics during the 1st quarter worth about $43,000. GAMMA Investing LLC increased its stake in Apogee Therapeutics by 3,560.1% in the first quarter. GAMMA Investing LLC now owns 5,417 shares of the company's stock valued at $202,000 after purchasing an additional 5,269 shares during the last quarter. Finally, Optimize Financial Inc purchased a new stake in Apogee Therapeutics during the fourth quarter valued at about $203,000. 79.04% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of research analysts recently issued reports on the company. Citigroup started coverage on Apogee Therapeutics in a report on Thursday, March 13th. They issued a "buy" rating and a $95.00 price target for the company. Guggenheim reiterated a "buy" rating on shares of Apogee Therapeutics in a research note on Monday, February 10th. Finally, Wedbush restated an "outperform" rating and issued a $90.00 price target on shares of Apogee Therapeutics in a research note on Tuesday, March 11th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, Apogee Therapeutics currently has an average rating of "Buy" and an average target price of $94.60.
Get Our Latest Stock Analysis on APGE
Apogee Therapeutics Company Profile
(
Get Free Report)
Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Apogee Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apogee Therapeutics wasn't on the list.
While Apogee Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
